Biblio

Filters: Author is Bredeson, Christopher [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Cohen, J.A., Baldassari, L.E., Atkins, H.L., Bowen, J.D., Bredeson, C., Carpenter, P.A., Corboy, J.R., Freedman, M.S., Griffith, L.M., Lowsky, R., et al. (2019). AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.Biol Blood Marrow Transplant.

C

Prokopishyn, N.L., Logan, B.R., Kiefer, D.M., Sees, J.A., Chitphakdithai, P., Ahmed, I.A., Anderlini, P.N., Beitinjaneh, A.M., Bredeson, C., Cerny, J., et al. (2019). The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time.Biol Blood Marrow Transplant.

I

Hamilton, B.K., Liu, Y., Hemmer, M.T., Majhail, N., Ringdén, O., Kim, D., Costa, L., Stuart, R., Alousi, A., Pidala, J.A., et al. (2019). Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant.

Pasquini, M.C., Le-Rademacher, J., Zhu, X., Artz, A., DiPersio, J., Fernandez, H., Mineishi, S., Kamishohara, M., Mehta, J., Nakamura, Y., et al. (2016). Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.Biol Blood Marrow Transplant.

R

Rosko, A., Wang, H.-L., de Lima, M., Sandmaier, B., H Khoury, J., Artz, A., Brammer, J., Bredeson, C., Farag, S., Kharfan-Dabaja, M., et al. (2016). Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia.Am J Hematol.